# MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

> **NCT00121108** · PHASE3 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 2127 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Motavizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00121108
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11-15
- **Primary completion:** 2010-12-27
- **Final completion:** 2010-12-27
- **Target enrollment:** 2127 (ACTUAL)
- **Last updated:** 2022-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121108, "MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00121108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*